These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 10337430

  • 1. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs.
    Yanni JM, Sharif NA, Gamache DA, Miller ST, Weimer LK, Spellman JM.
    Acta Ophthalmol Scand Suppl; 1999; (228):33-7. PubMed ID: 10337430
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs.
    Yanni JM, Weimer LK, Sharif NA, Xu SX, Gamache DA, Spellman JM.
    Arch Ophthalmol; 1999 May; 117(5):643-7. PubMed ID: 10326962
    [Abstract] [Full Text] [Related]

  • 3. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
    Galatowicz G, Ajayi Y, Stern ME, Calder VL.
    Clin Exp Allergy; 2007 Nov; 37(11):1648-56. PubMed ID: 17877767
    [Abstract] [Full Text] [Related]

  • 4. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
    Leonardi A, Quintieri L.
    Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis.
    Sharif NA, Xu SX, Yanni JM.
    J Ocul Pharmacol Ther; 1996 Apr; 12(4):401-7. PubMed ID: 8951676
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
    Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA.
    J Ocul Pharmacol Ther; 1996 Apr; 12(4):389-400. PubMed ID: 8951675
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
    Rosenwasser LJ, O'Brien T, Weyne J.
    Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
    Abelson MB, Lanier RQ.
    Acta Ophthalmol Scand Suppl; 1999 Sep; (228):53-6. PubMed ID: 10337434
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Allergic conjunctival disorders].
    Ebihara N.
    Nihon Rinsho; 2005 May; 63 Suppl 5():107-13. PubMed ID: 15954334
    [No Abstract] [Full Text] [Related]

  • 17. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
    Leonardi A, Abelson MB.
    Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
    [Abstract] [Full Text] [Related]

  • 18. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms.
    Ahluwalia P, Anderson DF, Wilson SJ, McGill JI, Church MK.
    J Allergy Clin Immunol; 2001 Sep; 108(3):449-54. PubMed ID: 11544467
    [Abstract] [Full Text] [Related]

  • 19. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
    Netland PA, Leahy C, Krenzer KL.
    Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
    [Abstract] [Full Text] [Related]

  • 20. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
    Crampton HJ.
    Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.